A, low risk of bias:the study met almost criteria; B, moderate risk of bias :the study met part or unclear for one or more quality criteria; C, high risk of bias :the study was not met or included criteria;ANOVA:analysis of variance;ITT:Intention-to-treat;§NA: not available;
Figure 1 . PRISMA flow diagram demonstrating the progress of study evaluation throughout the review.
Figure 2 . Forest plots of (A):the relationship between patient with asthma or  allergic rhinitis use montelukast and the occurrence of neuropsychiatric events and (B): funnel plot of the included studies.
Figure 3 . Forest plots of patients with asthma or rhinitis have been linked to a neuropsychiatric event called headache
Figure 4 . Forest plots of (A):the relationship between the use of montelukast and neuropsychiatric events in asthma patients and(B)the relationship between the use of montelukast and neuropsychiatric events in patients with rhinitis.
Figure 5 . Forest plots of (A):the relationship between montelukast and neuropsychiatric events in adult patients with asthma or rhinitis and (B): the relationship between montelukast and neuropsychiatric events in children patients with asthma or rhinitis.
Figure 6 . Funnel plot of(A):the included studies based on the patient with montelukast or common clinical drugs analysis and forest plots of (B):the  neuropsychiatric events between montelukast and budesonide versus budesonide alone in asthmatic patients and (C): the occurrence of neuropsychiatric events in patients with allergic rhinitis compared with montelukast combined with loratadine versus loratadine alone